前收盘价格 | 32.78 |
收盘价格 | 33.55 |
成交量 | 1,722,019 |
平均成交量 (3个月) | 1,405,119 |
市值 | 49,323,384,832 |
市盈率 (P/E TTM) | 25.00 |
预期市盈率 (P/E Forward) | 22.99 |
价格/销量 (P/S) | 7.03 |
股市价格/股市净资产 (P/B) | 6.33 |
52周波幅 | |
利润日期 | 24 Apr 2025 |
股息率 (DY TTM) | 5.56% |
营业毛利率 | 26.15% |
营业利益率 (TTM) | 33.00% |
稀释每股收益 (EPS TTM) | 1.38 |
季度收入增长率 (YOY) | 7.90% |
季度盈利增长率 (YOY) | 21.50% |
总债务/股东权益 (D/E MRQ) | 15.14% |
流动比率 (MRQ) | 3.41 |
营业现金流 (OCF TTM) | 1.65 B |
杠杆自由现金流 (LFCF TTM) | 1.20 B |
资产报酬率 (ROA TTM) | 14.01% |
股东权益报酬率 (ROE TTM) | 25.81% |
市场趋势
短期 | 中期 | ||
行业 | Medical Instruments & Supplies (AU) | 混合的 | 混合的 |
Medical Instruments & Supplies (全球的) | 看跌 | 混合的 | |
股票 | RESMED CDI 10:1 [RMD] | - | - |
AIStockmoo 评分
分析师共识 | 0.0 |
内部交易活动 | NA |
价格波动 | 2.0 |
技术平均移动指标 | 2.5 |
技术振荡指标 | 4.0 |
平均 | 2.13 |
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting. |
|
部门 | Healthcare |
行业 | Medical Instruments & Supplies |
投资方式 | Mid Growth |
机构持股比例 | 9.36% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。
投资组合